NeuroMetrix Reports DPNCheck Introduction at the Annual Meeting of the China Diabetes Society

WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #neurometrix–NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today reported that DPNCheck®,
a diagnostic test for peripheral neuropathy, will be introduced at the 20th
Scientific Meeting of the Chinese Diabetes Society during November
16-19, 2016 in Xiamen, Fujian, China. DPNCheck is registered as a Class
II Medical Device with the China Food and Drug Administration (CFDA) and
marketed by Omron Beijing Ltd. The introduction will include exhibition,
demonstrations, and technical consultations for physicians and other
healthcare professionals attending the meeting.

China is dealing with an epidemic of diabetes. According to a recently
published study in the Journal of the American Medical Association
(JAMA), the prevalence of diabetes in the Chinese population has risen
dramatically over the past decades to nearly 12% today. The
International Diabetes Federation (IDF) estimated in 2014 that over 96
million people in China had diabetes. This represents nearly 25% of the
IDF estimated worldwide population of 387 million people with diabetes.

“Omron Beijing is leading the marketing and operational planning for
launch of DPNCheck in China,” said Shai N. Gozani, M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix. “The launch is
scheduled for selected regions late in Q4 with expansion during 2017. We
believe that DPNCheck addresses an important void in the care of persons
with diabetes and that China offers us a significant market opportunity.”

About DPNCheck

DPNCheck is a rapid, accurate and quantitative point-of-care test to
detect diabetic peripheral neuropathy, or DPN, at an early stage
allowing physicians to select appropriate treatment. DPN is the most
common complication of diabetes, affecting over half of people with
diabetes. It causes significant morbidity including pain, increased risk
of falling in the elderly, and is the primary trigger for diabetic foot
ulcers which may require lower extremity amputations. DPNCheck is
marketed in the U.S. to Medicare Advantage providers for profiling their
patient population well as guiding treatment. It is marketed in Japan by
Omron Healthcare and in Mexico by Scienta Pharma. For product
information visit http://www.DPNCheck.com/.

China Diabetes Society

Established in 1991 in Shanghai, the Chinese Diabetes Society (CDS) is
the leading national organization in the fight against the deadly
consequences of diabetes in China. The mission of the CDS is to prevent,
care and cure diabetes through education, research and good medical
practice. The CDS has 31 provincial and municipal branch societies and
more than 3,000 members across China and 6 study groups. The Society
supports diabetes research, promotes awareness of diabetes to the
general public, advocates on behalf of people affected by diabetes, and
coordinates academic cooperation among physicians, researchers and other
professionals working on diabetes.

About Omron

Omron Healthcare, headquartered in Kyoto, Japan, is a global leader in
health care monitoring. The company offers a wide range of devices and
services that help prevent and manage lifestyle diseases such as blood
pressure monitors, body composition monitors and activity counters as
well as medical devices such as vascular screening devices and visceral
fat monitors in more than 100 countries. For more information on Omron
Healthcare, visit www.healthcare.omron.co.jp/english/.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell®, an over-the-counter
wearable therapeutic device for chronic pain. Quell is integrated into a
digital health platform that helps patients optimize their therapy and
decrease the impact of chronic pain on their quality of life. The
company also markets DPNCheck, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

Contacts

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com